A systematic review of health effects of electronic cigarettes  by Pisinger, Charlotta & Døssing, Martin
Preventive Medicine 69 (2014) 248–260
Contents lists available at ScienceDirect
Preventive Medicine
j ourna l homepage: www.e lsev ie r .com/ locate /ypmedReviewA systematic review of health effects of electronic cigarettesCharlotta Pisinger a,⁎, Martin Døssing b
a Research Centre for Prevention and Health, Glostrup Hospital, DK-2600 Glostrup, Denmark
b Medicinsk Afdeling, Frederikssund Hospital, DK-3600 Frederikssund, Denmark⁎ Corresponding author at: Research Centre for Preven
E-mail address: charlotta.pisinger@regionh.dk (C. Pisin
http://dx.doi.org/10.1016/j.ypmed.2014.10.009
0091-7435/© 2014 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 16 October 2014Keywords:
Electronic cigarette
E-cigarette
ENDS
Electronic nicotine delivery system
Electronic nicotine delivery device
Objective: To provide a systematic review of the existing literature on health consequences of vaporing of
electronic cigarettes (ECs).
Methods: Search in: PubMed, EMBASE and CINAHL. Inclusion criteria: Original publications describing a
health-related topic, published before 14 August 2014. PRISMA recommendations were followed. We identiﬁed
1101 studies; 271 relevant after screening; 94 eligible.
Results: We included 76 studies investigating content of ﬂuid/vapor of ECs, reports on adverse events and
human and animal experimental studies. Serious methodological problemswere identiﬁed. In 34% of the articles
the authors had a conﬂict of interest. Studies found ﬁne/ultraﬁne particles, harmfulmetals, carcinogenic tobacco-
speciﬁc nitrosamines, volatile organic compounds, carcinogenic carbonyls (some in high but most in low/trace
concentrations), cytotoxicity and changed gene expression. Of special concern are compounds not found in con-
ventional cigarettes, e.g. propylene glycol. Experimental studies found increased airway resistance after short-
term exposure. Reports on short-term adverse events were often ﬂawed by selection bias.
Conclusions: Due to many methodological problems, severe conﬂicts of interest, the relatively few and often
small studies, the inconsistencies and contradictions in results, and the lack of long-term follow-up no ﬁrm con-
clusions can be drawn on the safety of ECs. However, they can hardly be considered harmless.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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The electronic cigarette (EC), also called e-cigarette, e-cig, electronic
vaping device, personal vaporizer or electronic nicotine delivery system
(ENDS) has been on the market for a decade. ECs are marketed as safe
products providing a sensation of traditional smokingwithout the harmful
effects, delivering pure nicotine and releasing harmless water vapor that
vanishes in seconds (Anon, 2014; Smoke, 2014). Pufﬁng activates the
battery-operated heating element in the atomizer and the liquid. The liq-
uid consists of various combinations of propylene glycol, glycerin, nicotine,
tobacco extracts, ﬂavorants and/or adulterants which vaporize to an aero-
sol/vapor. The newer generations of ECs seem to be very efﬁcient nicotine
delivery systems (Etter and Bullen, 2011a; Wall et al., 1988). Almost all
regular users use ECs with nicotine Etter and Bullen, 2011b.
In the beginning, ECswere primarily produced by smallmanufacturers
in China and sold on the Internet without drawing major attention. In the
last fewyears,major tobacco companies such as Lorillard, BritishAmerican
Tobacco, Altria, Reynolds and Imperial Tobacco have launched their own
ECbrands and are buying up existing ones.Marketing and sale has explod-
ed and EC-shops and -lounges pop-up everywhere. For the ﬁrst time in
more than 40 years tobacco companies are back on TV with cigarette
ads CNNMoney, 2014. Industrial economists project that the ECs will sur-
pass conventional cigarettes (CC) in about three decades, and the global EC
market is expected to hit $10 billion by 2017 (Lopes, 2013; Stocks, 2013).
The epidemic spread of this new product raises great concern in
some health and public health professionals sglanz, 2014 and great en-
thusiasm in others, who support the idea of “harm reduction” and see
the EC as a long-awaited alternative to the conventional cigarette. To-
bacco is the most deadly product on the market, and it is estimated
that it will cause 1 billion deaths in the 21st century Eriksen et al., 2012.
Discussions concerning this new product are characterized by strong
feelings andbeliefs, aswell as strongeconomic interests,making it verydif-
ﬁcult to obtain unbiased information. There are many important issues
concerning the EC, themost important being their long-termhealth effects.
The aim of this article is to give a systematic and critical review of the
existing literature on the health consequences of vaping of ECs and dis-
cuss the implications of our ﬁndings for public health. Furthermore, as a
ﬁrst, we want to investigate how many of the published articles have a
conﬂict of interest.
Objectives
We examined the published data to:
• Identify original publications on ECs which describe a health-related
topic.• Examine critically the design of the studies, the funding and other
conﬂicts of interest and their inﬂuence on conclusions drawn.
• Assess the existing evidence on the safety of ECs.
Methods
We have followed the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines whenever meaningful.
Eligibility criteria
Original articles or abstracts on ECs of any topic relevant to health. Published
before 14 Aug 2014— in any language.
Exclusion criteria
Recommendations, expert statements, reviews, technical reports and other
non-original papers. Papers on smoking cessation, abuse liability, nicotine levels,
withdrawal symptoms, poisonings, prevalence, attitudes and beliefs.
Search
A search was carried out in PubMed, EMBASE and CINAHL (Appendix 1, de-
tailed search).
Keywords: “electronic cigarette” or “e-cigarette” or “electrically heated ciga-
rette” or “ENDS and cigarette”or “electronic nicotine delivery system” or “electron-
ic nicotine delivery device” or “e-liquid”. No limits.
Study selection
We identiﬁed 2147 papers (Fig. 1).
Identiﬁcation
Screening of title left 1101 articles on ECs. After reading the abstract,
papers were rejected which did not report a health-related topic. Agree-
ment of authors was necessary to exclude a paper. Papers on symptoms
were included even if the main focus of the article was, for example,
smoking cessation, leaving n=271. Out of these, 177were duplicates, de-
scribed the same study population or did not report original data, leaving
94 papers. Full documents were obtained for the ﬁnal inclusion. Addition-
ally, we thoroughly looked through the reference lists of the articles for
missed papers and investigated reports for overlooked papers (Anon,
2012, 2013a,b; Burstyn, 2013; Schaller et al., 2013). Eight studies were
identiﬁed (Anon, 2009; Gennimata et al., 2014; Heavner et al., 2010;
Laugesen et al., 2008; Lauterbach and Laugesen, 2012; Lauterbach et al.,
2012; Trehy et al., 2011; U.S.Food and Drug Administration, 2009): one
was a laboratory analysis (U.S.Food and Drug Administration, 2009)
No. of records identified 
through database searching
2147
No. of records identified on 
basis of title: about electronic 
cigarettes  
1101                                      
No. of records excluded on
basis of title–clearly not about
electronic cigarettes
1046
No. of records screened on 
basis of abstracts: electronic 
cigarettes + health-relevant 
271
No. of records screened on
basis of abstracts: about
electronic cigarettes but not
health-relevant
830
Screening
Eligibility No. of full text articles or 
congress presentations 
assessed for eligibility                       
94
No. of duplicates/not original 
publications excluded
177
107
Identification
Inclusion
No. of additional records 
identified by reference search 
8
No. of full text articles or 
congress presentations 
included
76
No. of records excluded after 
thorough reading
26 
Fig. 1. Flowchart of publications included in the systematic review.
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six were excluded after reading the full text thoroughly (Farsalinos et al.,
2013a; Frost-Pineda et al., 2008a,b,c; Horvath, 2012; Kouretas et al.,
2012; Martin et al., 2012; Moennikes et al., 2008; Patskan and
Reininghaus, 2003; Roemer et al., 2008; Roethig et al., 2005, 2007, 2008;
Schorp et al., 2012; Stabbert et al., 2003; Terpstra et al., 2003; Tewes
et al., 2003; Tricker et al., 2009, 2012a,b,c,d; Urban et al., 2012; Werley
et al., 2008; Zenzen et al., 2012). Two abstracts were later published as a
full article (Kouretas et al., 2012), and the remaining articles investigated
electrically heated tobacco leaves. None of the additionally included stud-
ies have been published as full peer-reviewed articles.
Both authors read and discussed the articles. CP wrote the ﬁrst draft
of the paper. We investigated all papers for conﬂict of interest, funding
and workplace of authors. If in doubt, we contacted the authors and
asked about funding and conﬂict of interest and/or searched the
Internet.
Results
Summarizing the evidence
We found 34 studies investigating content/effect of e-ﬂuid or -vapor
(Anon, 2009; Bahl et al., 2012; Behar et al., 2014; Bertholon et al., 2013;
Cameron et al., 2013; Cervellati et al., 2014; Cheah et al., 2012; Czogala
et al., 2014; Etter et al., 2013; Fuoco et al., 2014; Goniewicz et al., 2013a,
b, 2014; Hadwiger et al., 2010; Hutzler et al., 2014; Ingebrethsen et al.,
2012; Kim and Shin, 2013; Kosmider et al., 2014; Laugesen et al.,2008; Lauterbach and Laugesen, 2012; Lauterbach et al., 2012;
McAuley et al., 2012; Park et al., 2014; Pellegrino et al., 2012;
Romagna et al., 2013; Ruprecht et al., 2014; Schober et al., 2014;
Schripp et al., 2013; Stepanov and Fujioka, 2014; Trehy et al., 2011;
Uryupin et al., 2013; Westenberger, 2009; Williams et al., 2013; Zhang
et al., 2013), 20 studies reporting adverse events (Bullen et al., 2010;
Camus et al., 2014; Caponnetto et al., 2013a,b; Chen, 2013; Dawkins
et al., 2013a; Etter, 2010; Farsalinos and Romagna, 2013; Farsalinos
et al., 2013b, 2014; Heavner et al., 2010; Hua et al., 2013a; Hureaux
et al., 2014; Lee et al., 2013a; McCauley et al., 2012; McQueen et al.,
2011; Monroy et al., 2012; Polosa et al., 2011, 2014a; Thota and
Latham, 2014), 21 human experimental studies (Battista et al., 2013;
Chorti et al., 2012; Czogala et al., 2012; Dawkins and Corcoran, 2013;
Dawkins et al., 2012, 2013b; Eissenberg, 2010; Etter and Bullen,
2011a; Farsalinos et al., 2012; Flouris et al., 2012, 2013; Gennimata
et al., 2014; Marini et al., 2014; Palamidas et al., 2014; Polosa et al.,
2014b; Tsikrika et al., 2014; Vakali et al., 2014; van Staden et al., 2013;
Vansickel et al., 2010, 2012; Vardavas et al., 2012) and one animal ex-
perimental study (Lim and Kim, 2014). In total, 76 studies (Fig. 1).Conﬂict of interest
In 26 studies (34%) the authors had a conﬂict of interest. Most stud-
ies were funded or otherwise supported/inﬂuenced by manufacturers
of ECs, but several authors had also been consultants for manufacturers
of medicinal smoking cessation therapy.
Table 1
Studies investigating the content/effect of ﬂuid or vapor of electronic cigarettes (n = 34).
Name of ﬁrst author
(reference year)
Conﬂict of
interest
(yes = ▲)
Reference product Fluid/
vapor
Conclusion
Bahl et al. (2012) No No ○ Fluid ○ Approx. one third of samples were highly cytotoxic to human embryonic stem cells and
mouse neural stem cells
Behar et al. (2014) No No ○ Fluid ○ Cinnamon ﬂavorings in reﬁll ﬂuids are linked to cytotoxicity
Bertholon et al.
(2013)
No CC and water pipe ○ Vapor ○ Contrary to CC smoke, which has a half-life in air of 19 to 20 min, the half-life of EC is very
short and risk of passive “smoking” exposure from EC is modest
Cameron et al. (2013) No No ○ Fluid ○ Large variability in nicotine concentrations was found
Cervellati et al. (2014) No CC ○ Vapor ○ Exposure to EC vapors is far less toxic than exposure to CC smoke
Cheah et al. (2012) No No ○ Fluid ○ Contained nicotine even though they claimed to be nicotine free
○ Signiﬁcant difference in the nicotine content across EC with same label, brand-to-brand and
cartridge-to-cartridge variations
○ Polycyclic aromatic hydrocarbons and TSNAs compounds were not found
Czogala et al. (2014) ▲ CC ○ Vapor ○ Using EC in indoor environments may involuntarily expose non-users to nicotine but not to
toxic tobacco-speciﬁc combustion products
Etter et al. (2013) ▲Yes No ○ Fluid ○ Half of the liquids analyzed contained up to ﬁve times the maximum amount of impurities
speciﬁed in the European Pharmacopoeia
Fuoco et al. (2014) No CC ○ Vapor ○ Particle number distribution modes of the EC-generated vapor were similar to the CC
○ ECs were found to be a major particle source, which can lead to signiﬁcantly high deposition
in vapers
Gennimata et al.
(2014)
▲ CC ○ Fluid
and vapor
○ There is very little risk of nicotine toxicity from major EC brands in the United Kingdom.
○ Nicotine concentration in e-liquid is not well related to nicotine in vapor
○ None of the tested products reached nicotine concentrations as high as CC
Goniewicz et al.
(2013a)
▲Yes Medicinal nicotine
inhalator, CC
○ Vapor ○ Toxic compounds: metals, carbonyls and volatile organic compounds were found in almost all
EC, but much lower levels than in CC smoke
○ Vapor of some EC contains traces of carcinogenic nitrosamines
○ Exposure to carcinogenic formaldehyde comparable with CC smoking
Goniewicz et al.
(2013b)
▲Yes No ○ Vapor ○ Vapor contains nicotine, but EC brands and models differ in their efﬁcacy and consistency of
nicotine vaporization
Hadwiger et al.
(2010)
No No ○ Fluid ○ Presence of unapproved active pharmaceutical ingredients
○ Nicotine-free products contained nicotine
Hutzler et al. (2014) No No ○ Fluid
and vapor
○Many ECs labeled as ‘nicotine free’ contained nicotine
○ Release of aldehydes is strongly enhanced in the second half of the vaping period
○ The occurrence of aldehydes seems to be associated with lower liquid levels within the
cartridges (overheating of the wire?)
Ingebrethsen et al.
(2012)
▲Yes CC ○ Vapor ○ Particle diameters and particle number conc. as in CC smoke
Kim and Shin (2013) No No ○ Fluid ○ Almost all ﬂuids contained carcinogenic compounds, tobacco speciﬁc nitrosamines
○ High maximum conc. of total tobacco speciﬁc nitrosamines
○ Great variability in content of the four measured tobacco speciﬁc nitrosamines
Kosmider et al.
(2014)
▲ Glycerin, PPG/
mixture of both
○ Vapor ○ ECs might expose their users to the same or even higher levels of carcinogenic formaldehyde
than CC smoke
○ Vapors from EC contain toxic and carcinogenic carbonyl compounds
○ Both solvent and battery output voltage signiﬁcantly affect levels of carbonyl compounds in
EC vapors
Anon (2009)
(2 versions)
▲Yes CC ○ Fluid
and vapor
○ Very low score for toxic emissions (based on N50 toxicants)
○ Small particle size
○Mercury detected
Laugesen et al. (2008) ▲Yes CC ○ Fluid ○ Acetaldehyde, benzene, acrolein and tobacco speciﬁc nitrosamines detected at low levels
○Metals, CO and other VOCs at lower limits than detection
Lauterbach and
Laugesen (2012)
▲Yes CC ○ Vapor ○ Acetaldehyde, formaldehyde, TSNs and mercury detected
○ Compared to CC level of toxins and carcinogens was reduced by N90%
Lauterbach et al.
(2012)
▲Yes CC ○ Vapor ○ Tobacco speciﬁc nitrosamines, tar, formaldehyde, acetaldehyde, acrolein, and other toxins
found in vapor
○Most toxicants were reduced by over 98% compared with CC
McAuley et al. (2012) ▲Yes CC ○ Vapor ○ Ethylbenzene, benzene, toluene, and m/p xylenes acetone, formaldehyde, and acetaldehyde
detected
○ Tobacco speciﬁc nitrosamines: typically found at lower levels than tobacco smoke
○ Conc. of pollutants were generally orders of magnitude lower than in CC smoke
Park et al. (2014) No CC ○ Vapor ○ Preliminary analyses indicate the observed that EC-speciﬁc gene expression changes were
concordantly changed following CC-conditioned media exposure
Pellegrino et al.
(2012)
No CC ○ Fluid
and vapor
○ PG and VG are major ingredients — other ingredients = traces
○ PM in vapor: ﬁne + ultraﬁne particles
○ PM emissions are signiﬁcantly lower than in CC smoke
Romagna et al. (2013) ▲Yes CC ○ Vapor ○ Vapor from 1 out of 21 EC liquids examined had cytotoxic effects on cultured ﬁbroblast
○ CC: signiﬁcantly higher cytotoxicity
Ruprecht et al. (2014) No CC ○ Vapor ○ EC produce less PM than CC and therefore may be less hazardous in terms of secondhand
exposure
Schober et al. (2014) No No vaping ○ Vapor ○ EC are not emission-free — could be of health concern for users and secondhand smokers
○ Ultraﬁne particles can be deposited in the lung
○ Release of inﬂammatory signaling molecule NO
Schripp et al. (2013) No CC ○ Vapor ○ Prominent components in the gas-phase: 1,2-propanediol, 1,2,3-propanetriol, diacetin,
ﬂavorings, and traces of nicotine
○ Passive vaping must be expected
(continued on next page)
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Table 1 (continued)
Name of ﬁrst author
(reference year)
Conﬂict of
interest
(yes = ▲)
Reference product Fluid/
vapor
Conclusion
○ The aerosol size distribution alters in the human lung and leads to an exhalation of smaller
particles
Stepanov and Fujioka
(2014)
No No ○ Fluid ○ ECs with the same nicotine content, but different pH, may deliver different doses of nicotine
to users
○Most of the tested brands have basic pH — the long-term effect of chronic aero-digestive tract
exposure is not known
Trehy et al. (2011) No CC ○ Fluid ○ Some products were found to contain high conc. of nicotine when labeled not to contain
nicotine
○ The actual amount of nicotine delivered is likely to be highly variable
○ Transfer of rimonabant and amino-tadalaﬁl to the vapor phase is low
○ Impurity level is lower than for CC
Uryupin et al. (2013) No No ○ Fluid ○ The main components of mixtures were non-tobacco products
Westenberger (2009)
(FDA)
No Medicinal nicotine
inhalator
○ Fluid ○ Diethylene glycol in one cartridge
○ Detectable levels of carcinogens and toxic chemicals
Williams et al. (2013) No CC ○ Fluid
and vapor
○ Harmful or potentially harmful elements detected
○ Aerosol: signiﬁcant amounts of tin and other metals, silicate beads, and nanoparticles, mostly
higher than or equal to corresponding conc's in CC smoke
○ Fluid with tin particles was cytotoxic
Zhang et al. (2013) No CC ○ Vapor ○ CC produce more particles initially, but particle counts converge to a similar scale as the
aerosols condense
○ EC and CC produce aerosols having generally similar particle sizes
CC conventional cigarette
EC electronic cigarette
FDA US Food and Drug Administration
NO nitric oxide
PM particular matter
PPG propylene glycol
TSNAs tobacco speciﬁc nitrosamines
UFP ultra ﬁne particles
VG vegetable glycerin
VOCs volatile organic compounds
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see Appendix 2)
Most studies used CCs as reference and investigated concentrations
of several substances known to be toxic/carcinogenic in CCs.Many stud-
ies found that the product labels did not show the concentrations of sol-
vents and ﬂavorings.
Glycols
These are the major components in ECs. High amounts of propylene
glycol (also called 1,2-propandiol) and glycerin were found in studies
testing for these substances (Cheah et al., 2012; Etter et al., 2013;
Pellegrino et al., 2012; Schripp et al., 2013; Uryupin et al., 2013).
Nicotine
Several studies found a large variability in nicotine concentrations
across brands, labels and cartridges (Cameron et al., 2013; Cheah
et al., 2012; Goniewicz et al., 2013b; Hadwiger et al., 2010; Schober
et al., 2014; Trehy et al., 2011;Westenberger, 2009), others found small-
er variability (Goniewicz et al., 2014). Nicotine-free products were
found to contain nicotine, sometimes in high concentrations (Cheah
et al., 2012, 2014; Hadwiger et al., 2010; Hutzler et al., 2014; Trehy
et al., 2011), while others found that nicotine content corresponded to
labels on the bottles (Etter et al., 2013; Laugesen et al., 2008). One
study found the concentration of nicotine in vapor to be much lower
than in tobacco smoke (Czogala et al., 2014).
Particles
Some studies found that ECs and CCs produce aerosols with compa-
rable particle sizes (Fuoco et al., 2014; Ingebrethsen et al., 2012; Zhang
et al., 2013) with ﬁne and ultraﬁne particles in vapor (Pellegrino et al.,
2012), but one study found particles from ECs much smaller (Anon,
2009) and anothermuch bigger (Bertholon et al., 2013) than in tobacco
smoke. A study showed that the vapor size distribution alters in thehuman lung and leads to exhalation of smaller particles (Schripp et al.,
2013). Regarding particle concentration, two studies found this to be
the same as in tobacco smoke (Fuoco et al., 2014; Ingebrethsen et al.,
2012), while three found the concentration to be lower, up to an order
of magnitudes lower, than in smoke (Czogala et al., 2014; McAuley
et al., 2012; Pellegrino et al., 2012) and one study found that CCs pro-
duce more particles initially, but particle counts converge to a level
comparable to the condensed vapor Zhang et al., 2013. Two ‘real-life’
condition studies found that vaping ECswith nicotine showed onlymar-
ginal particulate matter production in indoor air, while it was much
higher after vaping ECs without nicotine (Ruprecht et al., 2014;
Schober et al., 2014). The half-life of vapor was found to be very short
– seconds – due to rapid evaporation (Bertholon et al., 2013).
Cytotoxicity
One study found that several samples were highly cytotoxic to
human embryonic and mouse neural stem cells, and cytotoxicity was
due to ﬂavors. Cinnamon had a strong cytotoxic effect (Bahl et al.,
2012). E-ﬂuid containing tin particles was found to be cytotoxic on
human pulmonary ﬁbroblasts (Williams et al., 2013). However, other
studies found that vapor from only one out of 21 e-ﬂuids had cytotoxic
effects on culturedmurine ﬁbroblasts Romagna et al., 2013 and CCs had
signiﬁcantly higher cytotoxicity (Cervellati et al., 2014; Romagna et al.,
2013).
Metals
A study found that concentrations of lead and chromium in vapor
were within the range of CCs, while nickel was up to 100 times higher
than in CCsWilliams et al., 2013. One puff of EC-vapor contained numer-
ous particles, mainly tin, silver, nickel and aluminum. Tin, chromium,
andnickelwere foundasnano-particles. Another study found cadmium,
nickel and lead in almost all vapors of 12 brands but the amounts of
toxic metals were low, comparable with amounts contained in a nico-
tine inhaler (nicotine replacement treatment, NRT) (Goniewicz et al.,
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detection (Laugesen et al., 2008) and trace quantity of mercury in
vapor (Anon, 2009). A ‘real-life’ study showed a 2-fold increase of alu-
minum in indoor air after vaping (Schober et al., 2014).
Tobacco-speciﬁc nitrosamines (TSNAs)
Some studies found highmaximum concentrations of total TSNAs in
the vapor ofmost (Goniewicz et al., 2013a), or almost allﬂuids (Kim and
Shin, 2013). Other studies found carcinogenic TSNAs present in vapor at
lower levels than tobacco smoke (McAuley et al., 2012) or at trace levels
(Lauterbach and Laugesen, 2012; Lauterbach et al., 2012). Some studies
detected TSNAs with no/weak carcinogenic effect or no TSNAs in the
ﬂuid (Cheah et al., 2012; Etter et al., 2013; Schober et al., 2014;
Westenberger, 2009).
Carbonyls
In one study the potential human carcinogens formaldehyde, acetal-
dehyde and acrolein were detected in the vapors of almost all ECs
(Goniewicz et al., 2013a). Exposure to formaldehyde was comparable
with smoking (Goniewicz et al., 2013a), as was also the case with
vapor from high-voltage devices (Kosmider et al., 2014). The highest
levels of carbonyls were observed in vapors generated from propylene
glycol-based solutions (Kosmider et al., 2014) or in the second half of
a vaping period, indicating overheating of wires (Hutzler et al., 2014).
A study concluded that most carbonyls were detected at low concentra-
tions in vapor, with the exception of acetone, formaldehyde, and acetal-
dehyde (McAuley et al., 2012). Formaldehyde, acetaldehyde and
acrolein were also found in another study, at concentrations approx.
1/10 of those in smoke from CCs (Lauterbach et al., 2012). One study
found acetaldehyde and formaldehyde at low levels (Lauterbach and
Laugesen, 2012) and another found acetaldehyde and acrolein in
vapor at low levels (Laugesen et al., 2008). The same author presented
similar ﬁndings in another study, but in a newer version of the same
abstract, acetaldehyde and acrolein were not mentioned (Anon, 2009).
Finally, one study found that the release of formaldehyde was below
the limit of detection (Schripp et al., 2013).
Volatile organic compounds (VOCs) such as toluene Czogala et al.
(2014) and p,m-xylene were identiﬁed in almost all vapors
(Goniewicz et al., 2013a). In one study, the concentrations were below
the level of detection (McAuley et al., 2012).
Polycyclic aromatic hydrocarbons (PAHs)
Studies found either no PAHs in ﬂuid (Cheah et al., 2012), or that
most PAHs were below detection level (Lauterbach and Laugesen,
2012; McAuley et al., 2012) or as traces, only (Lauterbach et al., 2012).
However, probably carcinogenic PAHs in indoor air increased by 20%
after vaping (Schober et al., 2014).
Other measures
Human bronchial cells that contained mutations found in
smokers at risk of lung cancer were grown in a culture medium
that had been exposed to vapor. The researchers found that cells ex-
posed to high-nicotine vapor showed a similar pattern of gene ex-
pression to those exposed to tobacco smoke (Park et al., 2014). A
study found that vapor induced the release of cytokines and pro-
inﬂammatory mediators (Cervellati et al., 2014). Another study
found that half of the liquids analyzed contained up to ﬁve times
the maximum amount of impurities speciﬁed in the European Phar-
macopoeia (Etter et al., 2013). The highly toxic diethylene glycol was
found in one cartridge in one study (Westenberger, 2009) but not in
another (Etter et al., 2013). One study found potentially harmful ad-
ditives, such as coumarin (Hutzler et al., 2014). Products advertised
as containing tadalaﬁl contained amino-tadalaﬁl (Hadwiger et al.,
2010; Trehy et al., 2011). Products advertised as containing
rimonabant, contained rimonabant plus an oxidative impurity of
rimonabant (Hadwiger et al., 2010). One study found signiﬁcantamounts of silicate beads in the aerosol (Williams et al., 2013). Most
nicotine-containing ECs have a basic pH N 9, which seems to inﬂuence
the doses of nicotine delivered (Stepanov and Fujioka, 2014).
Studies reporting adverse events (Appendix 3)
Reports on AE were often ﬂawed by selection bias. In most cases of
the reporting of adverse events causality could not be conﬁrmed. There-
fore, and due to limited space, we present details on AE in Appendix 3
only. No serious AE were reported in controlled prospective studies.
Most AE have been from the mouth/throat and the respiratory system,
but symptoms from many organ systems have been reported. On the
other hand, many regular EC users reported decrease in respiratory
symptoms and improvements in general health.
Human experimental studies (Table 2, for details see Appendix 4)
Most studies included smokers as volunteers and compared with a
reference, mostly own-brand CCs.
Adverse events (AE)
These were very similar to those reported in Appendix 3. There was
low reporting of AE in regular users, who were EC-naïve before study
start, with the most frequent being light-headedness, throat irritation,
dizziness, cough (Dawkins and Corcoran, 2013; Vakali et al., 2014; van
Staden et al., 2013).
Pulmonary system
Studies in EC-naïve smokers found that the same particle dose was
received aswith smoking and vaping (Marini et al., 2014), increased air-
way resistance (Marini et al., 2014; Palamidas et al., 2014; Vardavas
et al., 2012) and a concomitant decrease in speciﬁc airway conductance
(Palamidas et al., 2014), an increase in impedance and overall peripher-
al airway resistance (Vardavas et al., 2012); effects that are reminiscent
of those seen with tobacco smoking. Two studies found immediate re-
ductions in exhaled nitric oxide, similar to smoking (Marini et al.,
2014; Vardavas et al., 2012) and increased the release of the inﬂamma-
tory signaling molecule NO upon inhalation (FeNO) (Schober et al.,
2014) while another study found a decrease in FeNO (Vakali et al.,
2014). A study including both healthy volunteers and patients with
asthma and chronic obstructive pulmonary disease also showed that
10 min of vaping caused immediate signiﬁcant airway obstruction
(Gennimata et al., 2014) which is in contrast with a retrospective re-
view ﬁnding objective and subjective improvements in asthma out-
comes (Polosa et al., 2014b.) Another study found that short-term
usage was associated with increased ﬂow resistance even though
spirometry-assessed lung function was deemed normal (Chorti et al.,
2012). Passive, but not active vaping of one EC resulted in short-term
lung obstruction, indicating insufﬁcient inhalation by EC-naïve smokers
(Chorti et al., 2012). The last study found that short-term vaping of ECs
generated non-signiﬁcant decrease in lung function; approx. half of
what was seen in smoking (Flouris et al., 2013).
Cardiovascular system
Some studies in EC-naïve smokers found that short-term vaping re-
sulted in increased heart rate (Battista et al., 2013; Czogala et al., 2012;
Tsikrika et al., 2014; Vakali et al., 2014; Vansickel et al., 2012), an eleva-
tion in diastolic blood pressure (Battista et al., 2013; Czogala et al.,
2012), and a decrease in oxygen saturation (Vakali et al., 2014). Other
studies found no increase in heart rate (Eissenberg, 2010; van Staden
et al., 2013; Vansickel et al., 2010) or in blood pressure (van Staden
et al., 2013) but an increase in oxygen saturation (van Staden et al.,
2013). Active and passive vaping in EC-naïve smokers did not inﬂuence
the complete blood count (Flouris et al., 2012). One study using experi-
enced EC-users found a slight elevation in diastolic blood pressure, but
no effect on cardiac function (Farsalinos et al., 2012).
Table 2
Human experimental studies reporting health effects (n = 21).
Name of ﬁrst
author
(reference
year)
Conﬂict
of
interest
▲ = Yes
Reference
product
Method
Length of exposure
Numbers of participants Conclusions
Battista et al.
(2013)
No CC ○ Experimental study
○ Exposure: 4 min of smoking/
vaping
○ 12 regular users of EC ○ EC inhalation produces the same patho-physiological
cardiovascular effects of CC smoking
Chorti et al.
(2012)
No CC ○ Volunteers in CC group smoked 2
CC
○ Volunteers in EC group puffed 1 EC
○ 15 EC naive heavy-
smokers
○ Passive but not active EC vaping resulted in short-term lung
obstruction and increased cotinine
Czogala et al.
(2012)
No CC ○ A repeated measures design
○ Exposure: 5 min of smoking/
vaping
○ 42 EC naive daily smokers ○ Slight non-sign elevation in diastolic blood pressure, pulse
and carboxyhemoglobin
Dawkins and
Corcoran
(2013)
▲ No ○ A repeated measures design
○ Exposure: 1) Ten puffs 2) 1 h ad
lib use
○ 14 regular EC users ○ Low reporting of AE in regular users. Most frequent: light-
headedness, throat irritation and dizziness
Dawkins et al.
(2013b)
▲ 0 mg
nicotine
EC
○Within-subjects design
○ Exposure: 10 min ad lib use
○ 20 EC naive smokers ○ EC can effectively deliver nicotine to impact on cognitive
performance; improved time-based memory
Dawkins et al.
(2012)
▲ 0 mg
nicotine
EC
○Mixed experimental design
○ Exposure: 5 min ad lib use
○ 86 EC naive smokers ○ Improved nicotine withdrawal impaired concentration/
memory
Eissenberg
(2010)
No CC ○ Hemodynamic measurements
○ Exposure: Puffed ad libitum 10
times
○ 16 EC naive smokers ○ No increase in heart rate
Etter and
Bullen (2011a)
No No ○ Saliva sampling in current vapers
○ Exposure: daily vaping
○ 31 current users (30 daily
users) of EC
○ Cotinine levels in experienced vapers were similar to levels
previously observed in smokers and higher than in users of
nicotine replacement therapy
Farsalinos
et al. (2012)
No? CC ○ Hemodynamic
measurements + echocardiogram at
baseline and after smoking/vaping
○ Exposure: 1 CC or 7 min of vaping
of EC
○ 20 EC naive smokers and
20 EC users
○ Slight elevation in diastolic blood pressure but no effect on
cardiac function in experienced EC users
Flouris et al.
(2013)
No CC ○ Repeated-measures controlled
study
○ Exposure: 30 min of active/passive
smoking or vaping
○ 15 EC naive smokers and
15 never-smokers
○ Short term passive vaping generated small non-sign
decrease in lung function, approx. the half of smoking
○ Similar nicotinergic impact to CC
Flouris et al.
(2012)
No CC ○ Three experimental sessions;
active and passive exposure
○ Exposure: 2 CC within 30 min or ‘a
number of puffs’ within 30 min
○ 15 EC naive smokers and
15 never-smokers
○ Acute active and passive vaping did not inﬂuence complete
blood count indices in smokers and never smokers
Gennimata
et al. (2014)
No? ? ○ Exposure: vaping for 10 min ○ 8 never smokers and 24
EC naive smokers
○ Short-term exposure caused immediate airway obstruction
Marini et al.
(2014)
No CC ○ Experimental study
○ Exposure: 4 puffs
○ 25 smokers ○ Similar effect on human airways, and same particle dose
received with smoking and vaping
Palamidas
et al. (2014)
No No ○ Experimental study
○ Exposure: Gr. A: vaping in 10 min
○ 70 volunteers (27 with
asthma/COPD).
Smokers + never smokers
○ Increased airway resistance and a concomitant decrease in
speciﬁc airway conductance
Polosa et al.
(2014b)
▲ No ○ Retrospective review of changes in
lung function and asthma control
○ Exposure: 6 and 12 months
follow-up
○ 18 smoking asthmatics
who switched to regular EC
use
○ Study indicates that regular use of EC to substitute smoking
is associated with objective and subjective improvements in
asthma outcomes
Tsikrika et al.
(2014)
No No ○ Experimental study
○ Exposure: vaping in 10 min
○ 62 volunteers, non-
smokers + smokers: 28
with COPD/asthma
○ Increased heart rate and symptoms like cough and sore
throat
Vakali et al.
(2014)
No No ○ Experimental study
○ Exposure: vaping in 10 min
○ 64 volunteers, non-
smokers + smokers
○ Increased heart rate, palpitations and a decrease in SpO2
○ A decrease in fraction of exhaled nitric oxide
van Staden
et al. (2013)
▲ No ○ A single group within-subject
design
○ Exposure: switch to EC vaping in
2 weeks
○ 15 smokers switched to
EC, 2 drop-outs
○ Increase in oxygen saturation, no changes in blood pressure
and pulse rate, cough worse/improved
○ Phlegm increased in some but decreased in more
Vansickel et al.
(2010)
No CC ○ Repeated-measures controlled
study
○ Exposure: two, 10-puff EC bouts
○ 32 EC naive heavy
smokers
○ No changes in plasma nicotine and heart rate
○ No increase in CO
Vansickel et al.
(2012)
No CC ○ 4 within-subject sessions
○ Exposure: six 10-puff bouts-
separated by 30-mins
○ 20 EC naive heavy
smokers
○ Increase in heart rate
Vardavas et al.
(2012)
No EC with
cartridge
removed
○ Exposure: ad lib use for 5 min ○ 30 EC naive smokers of at
least 5 pack years
○ Increased ﬂow resistance
○ Immediate adverse effects on the airways after short-term
use; similar to some of the effects seen with smoking
EC = electronic cigarette; CC = conventional cigarette.
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Two studies found improved time-based but not event-based pro-
spective memory (Dawkins et al., 2013b) and improved nicotine with-
drawal impaired concentration/memory (Dawkins et al., 2012).
Other
A metabolite of the pyrolysis product acrolein was found in urine,
after vaping ECs with nicotine (Schober et al., 2014).
Animal study (Table 3, for detail see Appendix 5)
One study inmice treated intratracheally with EC ﬂuid increased the
inﬁltration of inﬂammatory cells, aggravated asthmatic airway inﬂam-
mation and airway hyper-responsiveness, and stimulated the produc-
tion of cytokines and ovalbumin-speciﬁc IgE production (Lim and Kim,
2014).
Discussion
Interpreting the ﬁndings
Our review included 76 studies investigating the health effects of
ECs. We included studies investigating content of ECs, reports on ad-
verse events, animal experiments and human experimental studies.
Due to the many methodological problems, severe conﬂicts of interest,
the relatively few and often small studies, the inconsistencies and con-
tradictions in results and the lack of long-term follow-up, no ﬁrm con-
clusions can be drawn on the safety of ECs, and much is left to
subjective interpretations.
A substantial number of studies were funded or otherwise support-
ed by manufacturers of ECs. Conﬂict of interest seems to inﬂuence the
conclusions of these papers. The content of e-liquid and vapor is charac-
terized by high amounts of propylene glycol, and sometimes glycerin,
nicotine and ﬂavors. Many ECs contain misleading/missing information
on product ingredients, especially nicotine, and many studies found
harmful substances: ﬁne/ultraﬁne particles, cytotoxicity, harmful
metals, carcinogenic tobacco-speciﬁc nitrosamines and carbonyls —
some inmost samples, others in few. Some studies found a high concen-
tration of harmful substances, as high as in CCs or higher, butmore stud-
ies found low or trace levels. Some ﬂavors, such as cinnamon were
found to have strong cytotoxic effects. One experimental in vitro study
found that EC vapor can change gene expression in a similar way to to-
bacco. Higher battery-output voltage increased the production of harm-
ful substances substantially, which was also the case with propylene
glycol-based solutions andwhen e-liquid levels decreased. The dangers
of secondhand exposure have not been thoroughly evaluated. A poten-
tially carcinogenic pyrolysis product was found in urine. Lungs are the
primary target organ and experimental studies have found effects
after very short-term exposure that are reminiscent of the obstructive
effects seen with smoking, even though the impact on lung function
was smaller than with smoking. An animal study found that EC ﬂuidTable 3
Animal experimental studies reporting health effects (n = 1).
Name of ﬁrst
author (reference
year)
Conﬂict of
interest
▲=Yes
Reference
product
Animal type and
number
Exposure
Lim and Kim
(2014)
No CC ○ 24 ﬁve-week-old
female BALB/c mice
○ Diluted solution
intra-tracheally
instilled to ovalbum
-sensitized mice tw
times a week for
10 weeks
EC = electronic cigarette; CC = conventional cigarette.can exacerbate allergy-induced asthma symptoms. A few experimental
studies have shown that ECs can effectively deliver nicotine to impact
on cognitive performance and the heart. Case reports on different lung
diseases and atrial ﬁbrillation found time association and/or reversibili-
ty, but causality can only be hypothesized. No serious AE were reported
in controlled prospective studies. No serious AE were reported in con-
trolled prospective studies. Most AE have been from the mouth/throat
and the respiratory system, but symptoms from many organ systems
have been reported. Regular EC users often reported improvements in
respiratory symptoms and general health. Findings were ﬂawed by
selection-bias.
This researchﬁeld is new and very challenging. Seriousmethodolog-
ical problems were identiﬁed. Core problems are: 1) Any research only
applies to the speciﬁc EC brand, model and batch tested, with no cer-
tainty that the ﬁndings will apply to other or future brands, models or
batches. ECs are subject to frequent modiﬁcations, and there are cur-
rently more than 460 brands. 2) Almost all studies have compared con-
centrations of harmful substances in CCswith concentrations in ECs, but
health hazards may be different than from smoking. 3) EC-use topogra-
phy is signiﬁcantly different than smoking (Hua et al., 2013a). When
vaping, you are sucking harder and have longer pufﬁng duration,
approx. double of smoking, especially if theﬂuid content in the cartridge
is low (Hua et al., 2013b). Therefore, the real uptake of harmful sub-
stances might be underestimated when testing on EC-naïve volunteers
or standard smokingmachines. Also, studies show signiﬁcant variations
in pufﬁng topography among users of various EC models (Farsalinos
et al., 2013a), that production of harmful substances is inﬂuenced by
both battery voltage output (Kosmider et al., 2014) and e-liquid levels
left (Hutzler et al., 2014), and that pH may inﬂuence the doses of nico-
tine delivered to users (Stepanov and Fujioka, 2014)— this complicates
the research even more. 4) Human experiments were mostly based on
very short-term exposure, e.g. vaping for a fewminutes— not reﬂecting
real-life exposure.
Of special concern are compounds not found in CCs: the glycols, pro-
pylene glycol and glycerin, major ingredients of ECs. Propylene glycol,
which creates the visible fume, is a solvent used in pharmaceutical
products and is “generally recognized as safe” (Anon, 2011). An internal
technical report commissioned by vapers and vendors of ECs concluded
that estimated levels of exposure to propylene glycol and glycerin are
close enough to threshold-limit values to warrant concern and that
the threshold-limit values are based on uncertainty rather than knowl-
edge (Burstyn, 2013). Volunteers exposed to propylene glycol mist for
1min developed a slight airway obstruction and increased self-rated se-
verity of dyspnea (Wieslander et al., 2001). Long-term exposure to pro-
pylene glycol has been found to exacerbate and/or induce multiple
allergic symptoms in children (Choi et al., 2010). Experimental studies
show moderate cytotoxic effect on skin ﬁbroblasts (Ponec et al.,
1990), irritation to the upper respiratory tract and squamousmetaplasia
of the epiglottis following exposure at concentrations present in ECs
(Renne et al., 1992). Ethylene glycol, associated with pronounced toxi-
cological risks (Hess et al., 2004), has been found to replace glycerol/Conclusions
was
in
o
○ Suggest that the inhalation of EC solutions can function as an important
factor to exacerbate the allergy-induced asthma symptoms
256 C. Pisinger, M. Døssing / Preventive Medicine 69 (2014) 248–260propylene glycol in several brands (Hutzler et al., 2014). Other concerns
are ﬂavors,metals, rubber, silicone and ceramics. Signiﬁcant amounts of
metals (probably originating from solder joints, wires etc.) and silicate
beads (probably from ﬁberglass wicks) have been found in ECs
(Williams et al., 2013). Occupational exposure to silicate dusts can
cause extensive pulmonary damage (Elmore, 2003). Lead and chromi-
um concentrations were found within the range of CCs, nickel was up
to 100 times higher than in CCs and e-ﬂuid containing tin was found
to be cytotoxic (Williams et al., 2013). These metals appear on the U.S.
Food and Drug Administration's “Harmful and Potentially Harmful
Chemicals” list (FDA, 2014).
Many of the harmful substances detected were identiﬁed at very low
concentrations but we are dealing with intense and chronic exposure.
Values below the threshold limit don't necessarily protect against the
health effect of 200–300 daily inhalations (Goniewicz et al., 2013b) over
decades— harmmight accumulate over years/decades, as with CCs. Fur-
ther, the presence of, for example, ten substances below the ofﬁcial
threshold-limit values may add up in a synergic way and the safety of
the combination of substances has not been evaluated. The inhaled aero-
sol may undergo changes in the human lung (Schripp et al., 2013). Long-
term inhalation of an aerosol may increase the risk of tuberculosis, as ob-
served in tobacco smoking (Bates et al., 2007). Additionally, there is
enough heat generated during pufﬁng (Schripp et al., 2013) to cause the
ﬂuid to decompose and/or components of the device to pyrolyze, where-
by toxic/carcinogenic substances may be formed. Flavors are also known
to affect the stability of products.
Discussions about levels of potentially harmful compounds in ECs often
remove the focus from the fact thatwe aredealingwith a very efﬁcient nic-
otine delivery system. Almost all regular users report that they use ECs
with nicotine (Etter and Bullen, 2011b), with levels in EC users (Etter and
Bullen, 2011a) as in smokers (Etter et al., 2000), and higher than in NRT
users (Benowitz et al., 1997). It iswell established thatnicotine is highly ad-
dictive (Benowitz, 1999; Picciotto and Corrigall, 2002). More than 60% of
smokers wish to quit because they don't like being dependent (Pisinger
et al., 2011) and switching to ECs does not break the nicotine addiction.
Nicotine is referred to by some health professionals as harmless,
whereas others do not share this view (National Center for Chronic
Disease Prevention and Health Promotion, 2014). A meta-analysis
found no increased risk of serious adverse events (Moore et al.,
2009). To our knowledge, only one study has investigated the health
effects of long-term pure nicotine/NRT use, ﬁnding no increase in the
risk of cancer (Murray et al., 2009). However, nicotine has a signiﬁ-
cant biologic activity: in the central nervous system nicotine stimu-
lates the release of important neurotransmitters and hormones
(Balfour, 1982), and in the peripheral system it stimulates the re-
lease of catecholamines, with effects such as vasoconstriction, in-
crease in heart rate and myocardial contractility (Kilaru et al.,
2001). Animal studies suggest that nicotine accelerates atherosclero-
sis (Kilaru et al., 2001), reduces sperm quality (Condorelli et al.,
2013), promotes growth of cancer cells and the proliferation of en-
dothelial cells, reduces the responsiveness of several cancers to che-
motherapy (Al-Wadei et al., 2009; Banerjee et al., 2013; Catassi et al.,
2008; Dinicola et al., 2013; Petros et al., 2012), and fetal and neonatal
nicotine exposure leads to widespread adverse postnatal physical
and mental health consequences (Bruin et al., 2010; Dwyer et al.,
2009; Gao et al., 2008). The applicability to human beings may be
questioned. Poison centers are receiving many calls regarding e-
ﬂuid (Kilaru et al., 2001); mostly exposures have resulted in minimal
toxicity (Vakkalanka et al., 2014), but a case of fatal nicotine poison-
ing in a child has been reported (Kloosterman, 2013).
Health professionals who advocate “harm reduction” compare ECs
with CCs, focus on smokers only, believe that ECs have no negative
long-term health effects, that nicotine is a harmless recreational drug
and that smokers are unwilling/unable to quit. These views are strongly
supported by the EC/tobacco industry. On the other hand, health profes-
sionals working with public health point out that CCs are the mostharmful legal products on themarket (everything seems safe compared
to smoking) and fear potential long-term health hazards. Other major
concerns are that the product is spreading to never-smokers and ex-
smokers, citizens unexposed to CCs, that many smokers have dual use
(using both products) or switch instead of quitting, and that widespread
EC-use will re-normalize smoking. This view is supported by the medical
industry producing smoking cessation products.
Are there good reasons for concern? It would be naïve not to expect
that the manufacturers will try hard to spread the use of their product to
as many consumers as possible; it is a billion dollar business and history
has shown that the tobacco industry has no ethical constraints and has
used every iteration of cigarette design to undermine prevention and ces-
sation (Bero, 2005; Proctor, 2011).
For several years ECs have been used as a healthier alternative to
smoking or as an aid to cut down or quit (Adkison et al., 2013; Etter and
Bullen, 2011b; Goniewicz et al., 2013c). Some prospective studies were
very promising about ECs' effect as a smoking reduction/cessation aid
(Caponnetto et al., 2013a,b), and a recent ‘real-life’ study showed that
ECs increased cessation ratesmore than no aid/NRT bought over the coun-
ter (Kotz et al., 2014). However, ameta-analysis based onpopulation stud-
ies found that ECuserswere signiﬁcantly less likely thannon-users to have
stopped smoking (Grana et al., 2014), a longitudinal study in cancer pa-
tients showed that EC-users were twice as likely to be smoking at the
time of follow-up as non-users (Borderud et al., 2014), and the only
existing randomized smoking cessation study showed that ECs were not
signiﬁcantly more effective than nicotine patch therapy (Bullen et al.,
2013). A survey sponsored by EC manufacturers found that only 1% of
EC users achieved permanent abstinence by the use of ECs (Heavner
et al., 2010); this study is not cited by harm reduction advocates. There
is evidence that ECs are often used for dual use (Adkison et al., 2013;
Etter, 2010; Etter and Bullen, 2011b; Lee et al., 2013b), as a supplement
to CCs e.g. in places with a smoking ban, by ex-smokers (Adkison et al.,
2013; Anon, 2013c; Etter, 2010; Etter and Bullen, 2011b) and by smokers
whoplanned toquit but instead switched to long-termuseof ECs, thereby
undermining complete cessation (Bullen et al., 2013). An experimental
study showed that EC exposure may evoke smoking urges in young
adult daily smokers (King et al., 2014). The last few years EC-use has
spread to minors and experimental use has doubled within one year
(Anon, 2013c; Anon, 2013d; Camenga et al., 2014). Surveys show that a
high proportion of adolescents have tried ECs (Goniewicz and
Zielinska-Danch, 2012; Dautzenberg et al., 2013; Czoli et al., 2014), even
children as young as 12–14 years (Dautzenberg et al., 2013). Of special
concern is that young never-smokers are experimenting with ECs
(Anon, 2013c,d; Czoli et al., 2014; Dautzenberg et al., 2013; Goniewicz
and Zielinska-Danch, 2012). A survey found that every ﬁfth of those
who were non-smokers when they started using ECs were also smoking
at time of survey, but there was no information as to whether they
were never-smokers or ex-smokers at initiation of EC-use (Goniewicz
et al., 2013c). To our knowledge, no studies have investigated whether
ECs are a gateway to smoking.
It is necessary to include all users and modes of use when discussing
beneﬁts or risks of ECs. Additionally, the use of ECs might undermine de-
cades of efforts to denormalize smoking (Choi et al., 2012).
We ﬁnd that it is of concern that the safety, manufacture, quality
control, labeling, sales and marketing of a product with unknown
long-term health consequences and exploding sales is more or less un-
regulated. Authorities have a responsibility to ensure that EC-users can
buy safe high-quality products with contents corresponding to the
label, and they also have the responsibility to prevent the spread of
the use of ECs to minors and non-smokers. Also, they must keep in
mind that the impact of a product on public health is determined by
two factors: 1) the degree of toxicity/harm of the substance; and
2) how widespread the exposure is. Even if ECs are less harmful than
CCs, the product may have a very negative impact on public health if
the use is spread to a large part of the population; ECs might achieve
popularity as high as that of CCs in the 1950s or 60s, before evidence
257C. Pisinger, M. Døssing / Preventive Medicine 69 (2014) 248–260and an awareness of harm became widespread in the population.
Health professionals and decision-makers must exercise the utmost
caution in trusting conclusions of studies/reviews where there is a con-
ﬂict of interest (Bero, 2005; Brezis, 2008; Proctor, 2011). Systematic re-
search is urgently needed (Etter et al., 2011).Conclusion
Due to the many methodological problems, the relatively few and
often small studies, the inconsistencies and contradictions in results
and the lack of long-term results, no ﬁrm conclusions can be drawn
on the safety of ECs. A substantial number of studies were published
by authors with a conﬂict of interest and we must exercise the utmost
caution in trusting their conclusions. Based on 76 studies, ECs cannot
be regarded as safe, even though they probably are less harmful than
CCs. The “harm reduction” strategy might be a gain for smokers reluc-
tant to quit but ex- and never-smokers probably have an increased
risk by using ECs. Combined with the imminent risk of undermining
smoking cessation and the renormalization of smoking the total risk
on public health from widespread use of ECs might be substantial.
Their use should, so far, be restricted to smokers unwilling/unable to
quit. Systematic research is urgently needed.Conﬂict of interest
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